Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-Label Study in Subjects With Parkinson's Disease to Evaluate the Safety and Tolerability of Titration and Continuous Subcutaneous Infusion of ABBV-951 for up to 4 Weeks in an Outpatient Environment

NCT03374917 is registered in ClinicalTrials.gov with AbbVie as lead sponsor.

NCT NCT03374917
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03374917 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-Label Study in Subjects With Parkinson's Disease to Evaluate the Safety and Tolerability of Titration and Continuous Subcutaneous Infusion of ABBV-951 for up to 4 Weeks in an Outpatient Environment
Lead sponsor
AbbVie
Phase
Phase 1
Overall status
Completed
Start date
April 18, 2018
Completion date
March 4, 2019
Enrollment
20 (actual)
Sites
12

Conditions

As the registry lists them; a condition with its own page is linked.

parkinson's disease (pd)